Evaluation of Antral Biopsies Obtained in Normal Esophagogastroduodenoscopy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

671 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-02-13

Study Completion Date

2024-02-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Esophagogastroduodenoscopy (EGD) is commonly performed in patients presenting with abdominal pain and dyspeptic symptoms, serving as a valuable diagnostic and therapeutic tool. While various methods are available for biopsy sampling when mucosal pathology is observed during EGD, the practice of obtaining biopsies from endoscopically normal mucosa remains controversial. Although there is literature suggesting that routine biopsies from the antrum and duodenum for surveillance purposes increase costs, pathological findings can sometimes be detected in areas that appear normal on mucosal examination, leading to potential changes in treatment approach if biopsies are obtained.

In this study, a retrospective evaluation of the prevalence of various pathologies detected in biopsies obtained from endoscopically normal mucosa in patients who underwent EGD was reported as normal.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study

NCT02675010

Helicobacter Pylori Gastric Antrum CORPUS BIOPSIES

UNKNOWN NA

Nausea and Vomiting Following Esophagogastroduodenoscopy: Prevalence and Predictive Factors

NCT06689046

Postoperative Nausea and Vomiting Esophagogastroduodenoscopy

COMPLETED

Pattern Of Endoscopic Findings In Patients Underwent Upper Endoscopy In Sohag University Hospital

NCT05820061

All Patients With Upper GIT Symptoms and Underwent Upper Endoscopy

COMPLETED NA

Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis

NCT05238181

Autoimmune Diseases Helicobacter Pylori Gastritis Anemia, Pernicious +2 more

UNKNOWN

Helicobacter Pylori Gastritis and Its Relation to Metabolic Syndrome Components

NCT06935955

Gastritis

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Esophagogastroduodenoscopy (EGD) is a commonly used diagnostic tool in upper gastrointestinal system diseases. Its widespread use is facilitated by its minimally invasive nature, the possibility of therapeutic procedures, low complication rates, and broad applicability. Although there are numerous guidelines regarding approaches to endoscopic pathologies and diseases detected during esophagogastroduodenoscopy, the necessity of biopsy sampling from mucosal areas that are endoscopically normal remains controversial.

In this study, patients aged between 18 and 95 who underwent EGD at the Sisli Hamidiye Etfal Training and Research Hospital Surgical Endoscopy Unit between 2021 and 2023, with no pathology detected during the endoscopic examination and who underwent biopsy sampling, will be evaluated. History of upper gastrointestinal surgery, detection of the endoscopic pathology, and not having biopsy sampling will be considered as exclusion criteria. The rate of detection of histopathological findings in the obtained biopsies, severity and activity of gastritis, rate and density of Helicobacter pylori detection, and rate and extent of intestinal metaplasia will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastritis H Pylori Gastritis Chronic Intestinal Metaplasia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

The biopsies obtained from patients who underwent esophagogastroduodenoscopy and were found to have normal endoscopic findings will be evaluated. The histopathological findings and their frequencies in these biopsies will be examined to assess the necessity of routine biopsy during esophagogastroduodenoscopy.

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal esophagogastroduodenoscopy

Patients with normal esophagogastroduodenoscopic findings and biopsy samples were obtained.

Group Type EXPERIMENTAL

Esophagogastroduodenoscopy

Intervention Type PROCEDURE

During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.

Endoscopic biopsy sampling

Intervention Type PROCEDURE

The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Esophagogastroduodenoscopy

During the procedure, endoscopic examination of the upper gastrointestinal tract was made. Biopsy sampling can be made during procedure if endoscopist deemed necessary.

Intervention Type PROCEDURE

Endoscopic biopsy sampling

The obtaining of biopsy samples for control purposes despite the absence of endoscopic pathology during esophagogastroduodenoscopy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged between 18-95
* Endoscopically normal esophagogastroduodenoscopy
* Sampling biopsies must be obtained

Exclusion Criteria

* History of upper gastrointestinal surgery
* Abnormal endoscopic findings such as gastritis, ulcer, hiatal hernia, pyloric deformity, alkaline reflux
* Not having biopsy

Minimum Eligible Age

18 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No